ORIGINAL RESEARCH | VOLUME 4, ISSUE 2 | OPEN ACCESS DOI: 10.23937/2474-3658/1510051

Assessment of Systemic Fungal Infections among Diabetic Patients in Enugu, Nigeria

Theophilus Kachi Udeani1*, Victoria Nneka Asogwa2 and Uche Ezenwaka3

1Department of Medical Laboratory Sciences, College of Medicine, University of Nigeria Enugu Campus, Nigeria

2Medical Microbiology Department, Enugu State University Teaching Hospital, Parklane, Enugu, Nigeria

3Department of Community Medicine, College of Medicine, University of Nigeria Enugu Campus, Nigeria

*Corresponding authors: Theophilus Kachi Udeani, Department of Medical Laboratory Sciences, Faculty of Health Sciences and Technology, College of Medicine, University of Nigeria Enugu Campus, Nigeria, Tel: +2348036255353.

Accepted: June 13, 2018 | Published: June 15, 2018

Citation: Udeani TK, Asogwa VN, Ezenwaka U (2018) Assessment of Systemic Fungal Infections among Diabetic Patients in Enugu, Nigeria. J Infect Dis Epidemiol 4:051. doi.org/10.23937/2474-3658/1510051

Copyright: © 2018 Udeani TK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract


Opportunistic invasive fungal infections are emerging health challenges worldwide, especially among immunocompromised hosts. This study investigated systemic fungal infections in diabetic patients. The diabetic patients were recruited from the Diabetic Clinics; Enugu State University Teaching Hospital Parklane, Enugu. A structured questionnaire was used to obtain information on the demographic and risk factors from the subjects. Sputum samples were collected from the patients and analyzed mycologically using Sabouraud dextrose agar with actidione and brain heart infusion agar fortified with 5% sheep red blood cells. Those with fungal growth were identified using needle mount, Gram stain and sugar fermentation/assimilation tests. Of 120 diabetic patients analyzed, 63 (52.5%) had fungal isolates. The females had higher isolates than the males, 36 (30%) and 27 (22.5%) respectively. The age range above 61-years-olds had more fungal isolates, 27 (22.5%) followed by those of 51-60 years-old with 21 (17.5%). The subjects with primary education had 24 (20%) of fungal isolates while those that were traders, 22 (18.3%) fungal isolates were obtained. The duration of diabetes was statistically significant as those with less than 5 years of diabetes had higher fungal infections of 40 (33.3%). The diabetic patients with FBS levels > 5.8 mmol/l had higher isolates, 51 (42.5%), (P = 0.001) while the subjects on insulin therapy and with persistent elevated fasting blood sugar level had 40 (33.3%) systemic fungal isolates. The frequency of fungal isolates showed that opportunistic and dimorphic fungi were implicated as infectious complications in diabetics. The dimorphic fungal isolates, Blastomyces dermatitidis 10 (8.3%) and Coccidioides immitis 6 (5%) are not common in this environment. These systemic fungal infections are of public health challenge due to its high transmission rate.

Keywords


Diabetes, Systemic mycoses, Dimorphic fungi, Insulin therapy, Enugu

Introduction


Opportunistic invasive fungal infections are emerging health challenges worldwide [1]. Severity of these fungal infections ranges from asymptomatic-mild mucocutaneous infections to life threatening systemic infections [2]. The main determinants of burden of fungal infections are linked to socio-economic, geographical characteristics and increasing number of at-risk populations. Individuals susceptible to fungal infections include those with immunosuppressive illnesses such as HIV/AIDS, tuberculosis, chronic pulmonary diseases (COPD), cancer and diabetes [3-5]. It has been reported that patients with systemic fungal infections are at high risk of disseminated fungemia and prolonged stay in hospital [6]. This scenario may be worsened if the patient has a metabolic disorder due to diabetes mellitus. This is because the diabetic patients are prone to high blood sugar concentration which weakens the immune system and causes several health complications [7].

In general, infectious diseases are more frequent and serious in patients with diabetes mellitus which potentially increases morbidity and mortality [8]. Diabetes mellitus is a clinical syndrome associated with deficiency of insulin secretion or action. It is considered as one of the largest threats to health in the 21st century. It is estimated that there will be 380 million people with diabetes in 2025, besides the classical complications of the diseases; diabetes has been associated with reduced response of T cell, neutrophil function and disorder of humoral immunity [9]. Diabetes increases susceptibility to various types of infection. The most common fungal infections consists of pulmonary aspergillosis, cryptococcal meningitis complicating HIV/AIDS, invasive candidiasis and mucormycosis [7,10,11].

The diabetic patients, due to their condition, lack adequate immunity to defend the body system against invading pathogenic fungal organisms thus they can be exposed to these agents either by inhalation of the spores of these fungal agents from the environment or by close contacts. The aim of this study was to determine the prevalence of systemic fungal infections in diabetic patients. The study also evaluated the risk factors and association of insulin therapy on outcome of systemic fungal infection.

Material and Methods


Study population

This is a cross-sectional survey carried out at Diabetic Clinic, Enugu State University Teaching Hospital (ESUT) between November 2015 and March 2016. The participants were recruited during normal routine check-up (out-patients) or those admitted into the hospital wards (in-patients). The participants selected were those with persistent cough and/or complaints of pneumonia.

A total of one hundred and twenty diabetic patients aged 18 years and above were recruited for the study. The diabetic patients with co-infections of human immunodeficiency virus and pregnant women were excluded from study. The information on insulin therapy was obtained from the patient’s hospital medical records.

A structured questionnaire was used to collect data about demographic factors, social life styles. All the participants completed and signed an Informed Consent Form.

Ethical considerations

The Ethical Committee of Ethical Review Board of ESUT Teaching Hospital Parklane Enugu revived and approved the study protocol.

Sample collection and mycological methods

Sputum samples were collected from the patients using sterile wide mouth container. The patients were well guided on the collection.

The sputum samples were inoculated onto Sabouraud dextrose agar, and brain heart infusion agar fortified with 5% sheep red blood cell and bird seed agar. They were incubated at 37 ℃ and observed for fungal growth daily for 14 days. The fungal isolates were processed using standard mycological techniques [12]. The agar plates with growth were grouped according to their morphological pattern: Those that appeared creamy and pasty were Gram-stained for the presence of yeast cells and by needle mount. Those that had hyphae spreading across the agar were identified by needle-mount using lactose-phenol cotton blue. The Candida isolates: were characterized by Germ-tube test, oxidation and assimilation test and Chlamydospore production.

Estimation of fasting blood sugar

Blood samples were collected from the participants and serum separated. The serum was used the estimate the fasting blood sugar by Glucose Oxidase Test.

Data Analysis


All data obtained from the questionnaire were matched with the results and entered in spread sheet. Descriptive statistics were used to obtain the mean ± SD of age FBS values and percentages. Chi-square test was used to compare the variables, and any case with P ≤ 0.05 was taken as being statistically significant. All data were analysed using SPSS version 21.

Results


Demographic characteristics of the diabetic patients

A total of 120 diabetic patients were enrolled for the study which comprises of 47 (39.2%) males and 73 (60.8%) females. The mean age of the subjects was 58.39 ± 11.15 (range of 26 to 80-years-old). Of the 120 diabetic patients, 63 (52.5%) had fungal isolates (Table 1). It was observed that there was no multiple fungal growths in each of the patients thus the colonization of the fungal isolates were specific for each participant. The frequency of the fungal isolates indicates that Candida species was 25 (20.8%) while Aspergillus species accounted for 22 (18.3%). The dimorphic fungi, Blastomyces dermatitidis and Coccidioides immitis were isolated at a frequency of 10 (8.3%) and 6 (5.0%) respectively. The Aspergillus species isolated included Aspergillus flavus 19 (15.8%) and Aspergillus niger 1 (0.8%) and Aspergillus fumigatus 2 (1.7%) while Candida albicans was 14 (11.7%), Candida kefyr 5 (4.2%) and Candida tropicalis 6 (5.0%) (Table 1).

Table 1: Summary of fungal isolates from diabetics. View Table 1

The gender distribution of the fungal isolates indicated that the females 36 (30%) had more fungal infections than the males 27 (22.5%), although the difference was not statistically significant (Table 2). The fungal isolates were obtained from the age group with an increasing frequency, those that were more than 61-years-old had the highest of 27 (22.5%) followed by those of age group 52-60 with 21 (17.5%) fungal isolates though it was not statistically significant. The assessment of educational background indicates that those with a maximum of primary education had the highest of 24 (20%) followed by the secondary school participants with 16 (13.3%). The participants without formal education and those of higher education showed fungal isolate of 9 and 14 respectively (7.5% and 11.7%).

Table 2: Demographic characteristics of the diabetic patients. View Table 2

The type of occupation, the participants engaged themselves, indicates that traders and civil servants had the highest isolates of systemic fungal infection 22 (18.3%) and 21 (17.7%). The artisans and housewives had 15 (12.5%) and 4 (3.3%) fungal isolates respectively (Table 2).

Risk factors for fungal infections

The risk factors that were assessed indicated that duration of diabetes was statistically significant for systemic fungal infection in diabetics, with a p = 0.010. The diabetic patients with less than 5 years duration had 40 (33.3%) fungal isolates than those with greater than 5-years, 25 (20.8%). The other parameters assessed, like family history of diabetics, previous antifungal therapy and previous antibiotic therapy were not statistically significant. Of importance are those that were on insulin therapy though not statistically significant, but remain vital. Out of 88 of the subjects that were on insulin therapy, 50 (56.8%) had systemic fungal infections. It was observed that none of the participants had a previous history of antifungal therapy (Table 3).

Table 3: Association of fungal Isolates with diabetic therapy and complications. View Table 3

Influence of fasting blood sugar

The fasting blood sugar was assessed along with fungal isolate and insulin therapy (Table 4). The subjects with higher fasting blood sugar had more isolates than those with normal FBS. The subjects with higher fasting blood sugar accounted for 51 (42.5%), with a mean of 158.6 ± 47.7 Mmol/L had higher fungal isolates as against those with normal FBS mean 94.3 ± 7.3 Mmol/L. The diabetic patients with non-response to insulin therapy indicates that those with higher FBS had more isolates than those with normal FBS 40 (45.5%) and 10 (11.4%) respectively.

Table 4: Assessment of fungal isolates in relation to fasting blood sugar and response to insulin therapy. View Table 4

Logistic regression analysis

The risk factors for fungal colonization in diabetic patients were subjected to multi-variate analysis. Duration of diabetes, non-response to insulin therapy and fasting blood sugar greater than 5.8 Mmol/L were respectively associated with systemic fungal infection in diabetic patients (Table 5).

Table 5: Multivariate analysis of risk factors for fungal infection. View Table 5

Discussion


Diabetic patients are prone to suppressed immunity due to excessive accumulation of sugar resulting from decreased insulin secretion [13]. The outcome of this scenario is that, the diabetic patients are exposed to opportunistic fungal infections. Thus the goal of this study was to assess systemic fungal infections in diabetic patients. This is important because in undiagnosed cases, pulmonary pneumonia may present a serious clinical problem in the affected diabetics.

The prevalence rate of 52.5% was very high and of public health concern. In a similar study in South Africa, Moore, et al. [14] reported that fungal infections in diabetics are twice higher than non-diabetics. The key risk factor for this high prevalence is increase in blood sugar level.

It has been reported that women are more infected with fungal infections. In this study, blood sugar levels of the diabetic patients were higher and most of them cannot be controlled by the use of insulin therapy, hence higher prevalence of fungal infections among this group. This was in line with the report of Santhosh, et al. [15], that fungal infections in diabetes can mean that blood glucose levels are not well controlled or that, the infection can spread to other parts of the body. A prevalent rate of 22.5% of total fungal infection was obtained from those within the age of 61 and above, thus the age difference among the diabetic remains a factor in systemic fungal infections. This may be due to interaction between aging and suppressed immunity due to diabetes [16].

The level of education had no impact on the outcome of fungal infection. It is expected that the higher the level of education the more concern about personal health, personal hygiene and overall health but in this study the systemic fungal infection was distributed among all the educational groups and those with primary education having a higher prevalence rate of 20%. This may be a chance occurrence because both those with tertiary education and secondary education shared in the systemic infection [8].

The duration of diabetes indicates that the patients that were newly diagnosed of diabetes had a greater prevalence of 33.3% than those that were diagnosed of diabetes for more than 5 years. This may be that, the diabetes was not diagnosed on time while opportunistic infection flourished in such patients before knowing their diabetic status [17].

Another important risk factor for systemic fungal infection in diabetes is the family history of diabetes; a total of 42.5% had no record to family diabetic lineage. It can be speculated that diabetes in this group of people may have been due to lifestyle and that they lack poor control measures in checkmating the diabetes, hence the increased prevalence of systemic fungal infection.

The frequency of fungal infection indicates that Aspergillus flavus constitutes the majority 17.5% of the fungal isolates. In contrast Santhosh, et al. [15] reported that Aspergillus fumigatus is the predominant species followed by Aspergillus flavus; but it has been noticed that in certain locales and hospitals, Aspergillus flavus is more common in air than Aspergillus fumigatus for unclear reasons hedayati, et al. [18]. Invasive Aspergillosis is evident in immunocompetent patients. Those with severe liver disease are at high risk for Aspergillus infection, which agreed with Panasiuk, et al. [19] that suggested that invasive Aspergillosis is a potential fatal complication of severe liver disease. This is as a result of immunosuppression following liver transplantation. However, liver disease alone predisposes to bacterial and fungal infection as a result of a depression of both humoral and cell-mediated immunity [20]. From this study, the isolation of Candida species was higher than other fungal isolates which is in agreement in a review by Richardson and Lass-Fiori [21] who stated that the rising incidence of Candida species can attributed to several risk-factors that are prevalent in critically ill patients such as debility, underlying malignancy, blood and bone marrow transplantation, AIDS, prolonged stay in intensive care unit (ICUs) and hospital stay, neutropenia, use of antibiotics and corticosteroids, and administration of parenteral alimentation.

The development of candidaemia however strongly implies immunodeficiency since it often occurs in immunocompromised patients, myeloproliferative disorders or leukaemia and patients with AIDS [22]. The rising incidence of Candida infection and Candidaemia can be attributed to a variety of mostly endogenous and exogenous factors [23].

The occurrence of Blastomyces dermatitidis and Coccidioides immitis are of public concern because these dimorphic fungi are not common in this environment because of its weather and lack of soil salinity [24] but can be as a result of occupational hazards or occupational exposure to endemic regions with archeology and high dust exposure. This is in agreement with Crum, et al. [25] who stated that it is as a result of exposure to infected tissues or aerosols of infected secretions. The presence of these dimorphic fungi in diabetic patients is a major complication, and can lead to high mortality. In this environment, these fungi can be acquired due to travels to endemic areas [26] and consumption of animal reservoirs like bats especially not-well cooked ones [27]. The implication of these infections is that these agents might result in high rate of pulmonary pneumonia and tuberculosis-like infections [14]. Generally, Coccidioides species are highly infectious human pathogens which are able to establish a life-threatening respiratory disease in immunocompetent individuals [24].

In conclusion, diabetics are prone to higher frequency of fungal infections. These infections may be due to failure of insulin use, which may result from non-adherence to drugs and over-use of insulin. Also, some fungal agents like Blastomyces dermatitidis and Coccidioides immitis which are not common in our environment [28] are of public health challenge due to high transmission rate of these dimorphic fungal infections. Antifungal drugs should be included in the routine drugs of diabetes patients. Early screening of the patients is important in the control and management of the infection.

References


  1. Singh N (2001) Trends in the epidemiology of opportunistic fungal infections: Predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 33: 1692-1696.

  2. Bongomin F, Gago S, Oladele RO, Denning DW (2017) Global and multi-national prevalence of fungal diseases-Estimate precision. J Fungi (Basel) 3: 57.

  3. Upton A, Marr AR (2006) Emergence of opportunistic mould infections in the haematopoietic stem cell transplant patients. Curr Infect Dis Rep 8: 434-441.

  4. Limper AH, Adenis A, Le T, Harrison TS (2017) Fungal infections in HIV/AIDS. Lancet Infect Dis 17: e334-e343.

  5. Armstrong-James D, Meintjes G, Brown GD (2014) A neglected epidemic: Fungal infections in HIV/AIDS. Trends Microbiol 22: 120-127.

  6. Richardson MD (2005) Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 56.

  7. Kotran R (2007) Essentials of Basic Pathology. In: Obesity, Diabetes Mellitus and Metabolic Syndrome. (7th edn), Elsevier, 494.

  8. Fluvbjerg A (2010) Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol 6: 94-101.

  9. Peleg AY, Weerar-than T, McCarthy JS, Davis TM (2007) Common infections in diabetes: Pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 23: 3-13.

  10. Bansel E, Garg A, Bhatia S, Attri AK, Chander J (2008) Spectrum of microbial flora in diabetic foot ulcers. Indian J Pathol Microbiol 51: 204-208.

  11. Enoch DA, Ludiam HA, Brown NM (2006) Invassive fungal infections: A review of epidemiology and management options. J Med Microbiol 55: 809-818.

  12. Beneke ES, Rogers AL (1996) Medical Mycology and Human Mycosis. Star Publish, Belmont, C.A., 1-239.

  13. Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, et al. (2005) Increased risk of common infection in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 41: 281-288.

  14. Moore PA, Zgibor JC, Dasanayake AP (2003) Diabetes: A growing epidemic of all ages. J Am Dent Assoc 134.

  15. Santhosh YL, Ramanath KV, Naveen MR (2011) Fungal infection in diabetes mellitus: An overview. Int J Pharmaceut Sci Rev Res 7: 221-225.

  16. Khaled H, Abu-Elteen, Hamad MA, Salah SA (2006) Prevalence of oral Candida infections in diabetic patients. Bahrain Med Bull 28: 1-8.

  17. Stoeckle M, Kaech C, Trampuz A, Zimmerl W (2008) The role of diabetes mellitus in patients with bloodstream infection. Swiss Med Wkly 138: 512-519.

  18. Hedayati MT, Pasqualotto AC, Warn PA, Bowyer P, Denning DW (2007) Aspergillus flavus: Human pathogen, allergen and mycotoxin producer. Microbiology 153: 1677-1692.

  19. Panasiuk A, Wysocka J, Maciorkowska E (2005) Phagocytic and oxidative burst activity of neutrophils in the end stage of liver cirrhosis. World J Gastroenterol 11: 7661-7665.

  20. Cornillet A, Camus C, Nimubona S, Gandemer V, Tattevin P, et al. (2006) Comparison of epidemiological, clinical and biological features of invasive aspergillosis in neutropenia and nonneutropenic patient: A 6-year survey. Clin Infect Dis 43: 577-584.

  21. Richardson M, Lass-Fiori C (2008) Changing epidemiology of systemic fungal infections. Clin Microbial Infect 14: 5-24.

  22. Pfaller M, Diekema DJ (2007) Epidermiology of invasive Candidiasis: A persistent public health problem. Clin Microbiol Rev 20: 133-163.

  23. Bassetti M, Trecarichi EM, Right E, Sanguinetti M, Bisio F, et al. (2007) Incidence, risk factors and predictors of outcome of Candidemia. Survey in 2 Italian University Hospitals. Diagn Microbiol Infect Dis 58: 325-331.

  24. Del Rocio Reyes-Montes M, Perez-Hultron MA, Ocana-Monroy JL, De-Leon MGF, Martinez-Herrara E Arenas R, et al. (2016) The habitat of coccidioides Spp. and the role of animals as reservoirs and disseminators in nature. BMC Infect Dis 16: 550.

  25. Crum N, Lamb C, Utz G, Amundson D, Wallace M (2002) Coccidioidomycosis outbreak among United State Navy seals training in a Coccidioides immitis-endemic-area--Coaling, California. J Infect Dis 186: 865-868.

  26. Cairns L, Blythe D, Kao A, Pappagianis D, Kaufman L, et al. (2000) Outbreak of coccidioidomycosis in Washington state residents returning from Mexico. Clin Infect Dis 30: 61-64.

  27. Cordeiro Rde A, e Silva KR, Brilhante RS, Moura FB, Duarte NF, et al. (2012) Coccidioides possadaii infection in bats, Brazil. Emerg Infect Dis 18: 668-670.

  28. Brown J, Benedict K, Park BJ, Thompson111 GR (2013) Coccidioidomycosis: Epidemiology. Clin Epidomiol 5: 185-197.